BioCardia, Inc.
BCDA evidence brief
What we can confirm
- BioSniper Score:
- 8.9 / 10
- Market Cap:
- $16.3M
What it means
What to watch
Prepared research question
What matters most for BCDA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCDA
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, with a lead program in ischemic heart failure.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$16.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for BioCardia, Inc..
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, with a lead program in ischemic heart failure.
- Clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases [sec_mda · as of 2026-03-24].
- Lead program: CardiAMP® autologous mononuclear cell therapy platform for ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina [sec_mda · as of 2026-03-24].
- Cash & equivalents of $4.1M as of 2026-06-30 [sec]; net loss of $1.6M for the period [sec]; shareholders' equity of $2.7M [sec].
- Working toward a Shonin pre-market submission to Japan's PMDA in Q4 2026 [news · published 2026-09-23].
- Presented CardiAMP HF II trial design at the Heart Failure Society of America Annual Scientific Meeting in October 2026 [news · published 2026-10-07].
What works
- Two active clinical programs: a Phase I/II allogeneic MSC trial for ischemic heart failure and a Phase I/IIa allogeneic MSC trial for COVID-19 ARDS [catalyst].
- Regulatory progress in Japan with a planned Shonin submission in Q4 2026 [news · published 2026-09-23].
- Cash runway managed into 2027 according to recent earnings call [news · published 2026-08-13].
What to weigh
- Company has generated only modest revenues to date and does not expect product revenue until regulatory approval [sec_mda · as of 2026-08-12].
- Cash of $4.1M as of 2026-06-30 [sec] may not be sufficient to fund planned operations; the company anticipates needing additional funding [sec_mda · as of 2026-03-24].
- Future capital requirements are uncertain and depend on many factors including clinical trial progress, FDA acceptance, and regulatory outcomes [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Company is clinical-stage and focused on cardiovascular and pulmonary diseases
“We are a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs.”
SEC MD&A · March 24, 2026
No revenue expected until regulatory approval
“We do not expect to generate any revenue from sales of our autologous and allogeneic cell therapy candidates unless and until we obtain regulatory approval.”
SEC MD&A · August 12, 2026
Planned Shonin submission to Japan's PMDA in Q4 2026
“BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) in Q4 2026.”
News · September 23, 2026
Catalyst timeline
- 2023-08-23 · Phase I/II Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells (hMSCs) in Patients With Ischemic Heart Failure With Reduced Ejection Fraction (HFrEF) — Phase 2 start for allogeneic MSC trial in heart failure.
- 2026-01-04 · Phase I/IIa Study to Assess AllogeneiC Expanded Human Mesenchymal Stem Cell Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE CARD TRIAL) — Phase 1 start for allogeneic MSC trial in COVID-19 ARDS.
Risks & what to watch (3)›
Key risks
- Cash runway uncertainty — Cash of $4.1M as of 2026-06-30 may not be sufficient to fund planned operations; additional funding likely needed [sec_mda · as of 2026-03-24].
- No product revenue until approval — Company has only modest revenues and does not expect product sales until regulatory approval [sec_mda · as of 2026-08-12].
- Clinical and regulatory dependence — Future capital needs depend on trial progress, FDA acceptance, and regulatory outcomes [sec_mda · as of 2026-08-12].
What to watch
- Outcome of the planned Shonin submission to Japan's PMDA in Q4 2026 [news · published 2026-09-23].
- Progress of the CardiAMP HF II trial and any FDA interactions [news · published 2026-10-07].
- Cash runway and any new financing or partnership announcements [news · published 2026-08-13].
Sources: Catalysts · News · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run BioCardia, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioCardia, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.76
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
22 buys · 0 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$806K
| Holder | Shares | Value |
|---|---|---|
| cm management, llc | 130,000 | $157K |
| vanguard capital management llc | 124,591 | $151K |
| geode capital management, llc | 94,287 | $114K |
| vanguard fiduciary trust co | 66,270 | $80K |
| citadel advisors llc | 63,384 | $77K |
| susquehanna international group, llp | 38,827 | $47K |
| pingora partners llc | 35,739 | $43K |
| brown advisory inc | 35,538 | $43K |
| xtx topco ltd | 24,270 | $29K |
| commonwealth equity services, llc | 18,283 | $22K |
Showing top 10 of 18 institutional holders of BioCardia, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.8%
- Days to cover
- 2.7
- Shares short
- 165,816
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCDA short interestGovernance
Frequently asked questions
What is the AI investment thesis for BioCardia, Inc.?
BioCardia, Inc. is a clinical-stage biotechnology company developing autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases, with a lead program in ischemic heart failure.
Who is the CEO of BioCardia, Inc.?
Dr. Peter A. Altman Ph.D. is the chief executive officer of BioCardia, Inc. (BCDA).
Where is BioCardia, Inc. headquartered?
BioCardia, Inc. (BCDA) is headquartered in Sunnyvale, CA, United States.
What therapeutic areas does BioCardia, Inc. focus on?
BioCardia, Inc. develops therapies across Oncology, Gene Therapy, Cardiovascular, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.